Galectin Therapeutics Reports Third Quarter 2012 Financial Results

Published: Nov 12, 2012

NORCROSS, Ga.--(BUSINESS WIRE)--Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported its financial results for the third quarter and first nine months ended September 30, 2012. These results are included in the Company’s Quarterly Report on Form 10-Q, which has been filed with the SEC.

Back to news